What Happened?
Shares of life sciences tools company Agilent Technologies (NYSE: A) jumped 3.9% in the morning session after it announced the completion of its acquisition of Biocare Medical, a deal the company expects to boost revenue growth and margins.
Biocare Medical is a company focused on clinical pathology, offering solutions for cancer diagnostics and research. Agilent stated that the acquisition expands its pathology business and is expected to be accretive, meaning it will add to its top-line growth rate and margin profile within the first year. Additionally, the company anticipates the deal will begin contributing to its earnings per share approximately 12 months after the transaction's close, signaling a clear path to increased profitability from the new business.
The shares were trading at $137.61, up 4.5% from the previous close.
Is now the time to buy Agilent? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Agilent’s shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 28 days ago when the stock gained 16.1% on the news that the company reported an impressive first quarter (fiscal Q2) results.
Labs that underinvested in equipment during the 2022–2024 industry slowdown are now being forced to replace aging instrument fleets. CEO Padraig McDonnell described the replacement cycle as a "200-300 basis point tailwind" to LC growth and said it is not just replacements but share gains in competitive accounts simultaneously.
This matters because Agilent beat the top end of its own EPS guidance by $0.07, a margin of outperformance that signals the recovery in life sciences spending is running ahead of management's own expectations, not just analyst models. Pharma grew 6%, biotech grew at low double digits, and major end market (chemicals, environmental, diagnostics) was positive in the quarter. The GLP-1 drug wave is a structural tailwind
McDonnell cited explicitly: Agilent's instruments sit in QA/QC and development labs at exactly the pharmaceutical customers scaling production of weight-loss drugs. Critically, the company raised its full-year EPS guidance to $6.00-$6.10 from $5.90-$6.04, a meaningful step-up that reflects confidence in the second half. McDonnell also flagged that the company's internal "Ignite" operating system is now "structurally embedded" rather than being piloted, a signal that margin improvements are durable rather than one-off.
Agilent is flat since the beginning of the year, and at $137.61 per share, it is trading 12.5% below its 52-week high of $157.20 from November 2025. Investors who bought $1,000 worth of Agilent’s shares 5 years ago would now be looking at only $934.37.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
